Russian scientists have obtained important data on cancer treatment in pregnant women

Scientists of the N.M. Emanuel Institute of Biochemical Physics,N.M. Emanuel Institute of Biochemical Physics of the Russian Academy of Sciences together with the staff of the V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology, and Perinatology are conducting research on molecular and genetic features of pregnant women with cancer.

Increase the chances: a domestic drug is designed to help in the fight against cancer

Why is it important to enter the market of a Russian biosimilar of a well-known drug

As reported by experts, treatment of oncologic diseases against the background of pregnancy is one of the most poorly covered issues in oncology, the therapeutic tactics for such patients remains debatable. Scientists named breast cancer (BC), cervical cancer (CC), ovarian cancer (OC) as the most common ones.

At the first stage of treatment in these patients standardly used cytostatic chemotherapy, based on the use of drugs that inhibit the reproduction (more precisely, clonal proliferation) of malignant cells.

The team's research is devoted to identifying the peculiarities of expression of genes related to the glutathione system, involved in the neutralization of compounds entering the body, and the main transport protein in the placenta of pregnant women with breast cancer, RRMS and RN.

"A comprehensive study of molecular genetic characteristics of patients with cancer developed against the background of pregnancy, the first step to which is made in our work, is aimed at developing approaches to individualize the treatment of these patients," Tatiana Zavarykina, head of the group of molecular genetic studies of the N.M. Emanuel Institute of Biochemical Physics of the Russian Academy of Sciences, told Izvestia.

The continuation of the work is of high practical importance, the scientists emphasized, since the study of molecular genetic features of pregnant women with cancer can reveal new targets of therapy, prognostic markers of obstetric complications of breast cancer treatment, and opportunities for assessing the effectiveness of chemotherapy against the background of pregnancy. The work is supported by the Ministry of Education and Science of the Russian Federation.